Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338879 | 0.90 | KDM4E (0.37) | CNR2GRM2PIK3CAMTORKDM4E | |
| SCHEMBL339822 | 0.87 | CNR2 (0.45) | CNR2PDE10AALDH1A1 | |
| SCHEMBL338923 | 0.84 | CYP11B2 (0.34) | CNR2KDM4E | |
| SCHEMBL338679 | 0.79 | KDM4E (0.36) | CNR2KDM4E | |
| SCHEMBL339891 | 0.78 | DPP4 (0.39) | CNR2KDM4EALDH1A1 | |
| SCHEMBL339662 | 0.77 | KDM4E (0.35) | CNR2KDM4EALDH1A1 | |
| SCHEMBL339388 | 0.72 | DPP4 (0.43) | CNR2KDM4E | |
| SCHEMBL367649 | 0.72 | CNR2 (0.53) | CNR2PDE10AALDH1A1 | |
| SCHEMBL338998 | 0.71 | PIK3CA (0.41) | CNR2GRM2PIK3CAMTORKDM4E | |
| SCHEMBL338698 | 0.70 | PIK3CA (0.46) | CNR2GRM2PIK3CAMTORKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| EP-2004643-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113226-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | CNR2 2213/4885GRM2 2465/4885PDE10A 1219/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | CNR2 2213/4885GRM2 2465/4885PDE10A 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.